NewsRoom Articles - Page 102 of 154 - PsychedelicNewsWire (PNW)

WednesdayApr 07, 2021 12:30 pm

Psilocybin Has Potential to Curb the Global Obesity Crisis

Psychedelics substances such as psilocybin have been found to be helpful in treating obesity and weight issues. Healthline found that more than one-third of adults in America are obese. Nearly 17% of children, ages 2 to 19, are also considered obese. Additionally, obesity has been linked to more than 60 chronic illnesses, including cancer, stroke, heart disease and type 2 diabetes. Worldwide, obesity has gotten worse, and if a substance such as psilocybin can help fight obesity and weight issues, we may be looking at a potential game changer. Various psychedelic companies have been studying psychedelics, looking for ways to…

TuesdayApr 06, 2021 1:23 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes Pre-Clinical Studies, Progresses Two Drug Candidates

Cybin has completed more than 20 pre-clinical studies in record time. Company is advancing two new therapeutic candidates with enhanced, improved properties. Drug candidates are designed to treat serious psychiatric conditions with high unmet medical needs. Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, has completed key research studies both in vitro and in vivo. The company recently announced that it had completed its 20th pre-clinical study and had progressed two psychedelic investigational new drug candidates: CYB003 and CYB004 (https://ibn.fm/jDvFz). The studies were completed in record time, the company reported, in part because of close collaboration with…

TuesdayApr 06, 2021 12:30 pm

Researchers Find Traits That May Help Identify Study Subjects Who Could Benefit from Psychedelic Therapy

The number of studies that focus on psychedelics and the benefits they possess as therapies for various mental health conditions has increased tremendously in the last few years. Psychedelics such as LSD and psilocybin mushrooms have shown their potential as possible therapies for conditions such as depression and PTSD, and while many hope that these drugs will be approved as therapies soon, there are those who are concerned about the effects these drugs may have on patients who participate in clinical trials for their study. New research has identified traits that have been linked to negative and positive experiences on…

MondayApr 05, 2021 2:44 pm

Australian Researchers to Conduct Study on Managing Meth Addiction Using Psilocybin

Researchers from Sydney, Australia, are planning a clinical trial with the objective to discover whether administering psychedelics, specifically psilocybin, to individuals who use methamphetamines, commonly known as “meth,” could help manage their addiction. Psilocybin is the active psychedelic ingredient found in magic mushrooms. The scientists from St. Vincent’s Hospital, Darlinghurst, will administer psychedelic therapy to patients who are dependent on ice, or meth. A St. Vincent specialist in toxicology, clinical pharmacology and addiction medicine, lead researcher Dr. Jonathan Brett stated that he was extremely aware of the pressures to carry out the trial in the strictest scientific and ethical boundaries.…

ThursdayApr 01, 2021 12:17 pm

Lumenate App Takes Users on a Trip, Sans Psychedelics

Psychedelics went mainstream a few years ago, and with research on these substances and their therapeutic benefits still ongoing, various jurisdictions across the United States have been considering whether to legalize or decriminalize magic mushrooms as well as other entheogenic fungi and plants. Additionally, more companies are developing psychedelic compounds as consumer products or medications in a bid to profit from the incoming regulatory environment. One of these is Lumenate, a company founded by Jay Conlon and Tom Galea. The two inventors have devised a way to induce a semi-psychedelic state using a device that can be found everywhere in…

WednesdayMar 31, 2021 2:15 pm

Australian Government to Give $15M Grant for Psychedelics Research Focusing on Mental Health

The federal government of Australia will be granting $15 million to clinical studies that look into the use of psychedelics substances such as ecstasy and psilocybin mushrooms for the treatment of mental health conditions. This grant is an important breakthrough in the fight against mental illnesses, especially with nearly half of all adults in Australia set to face mental health issues in the course of their lives. Black Dog Institute, a medical research institute that is dedicated to studying mental health, found that one in five adults experience symptoms of mental conditions in any given year. In the country, that’s…

TuesdayMar 30, 2021 1:30 pm

Tryp Therapeutics (CSE: TRYP) (OTC: TRYPF) Files Provisional Patent for New Psychedelic Delivery Methods

Last week, Tryp Therapeutics issued a statement announcing the submission of a provisional patent to enhance how psychedelics are dispensed across various indications. Tryp Therapeutics is a pharmaceutical company engaged in the development of compounds with known activity and safety profiles for the treatment of rare ailments that currently have no approved treatments. The company has a psilocybin program called the PFN(TM) program that works on developing synthetic psilocybin as a new therapy for specific neuropsychiatric disorders. The patent details new techniques for the development, dosing and delivery of psychedelics, which may help decrease the time a patient spends in…

MondayMar 29, 2021 2:32 pm

Washington D.C. Psychedelics Decriminalization Measure Takes Effect

During the November 2020 elections, voters in Washington, DC, approved a ballot measure that would decriminalize fungi and plant-based entheogens. Last week, the measure came into effect, with a wide range of psychedelic substances such as ayahuasca and psilocybin officially becoming the lowest priority for local law enforcement. Despite this, activists from the Plant Medicine Coalition (“PMC”) who were behind the initiative are now calling for the enactment of additional laws to provide child and worker protections associated with the use of these fungi and plant-based substances. The activists are asking that the city provide guidelines to law enforcement about…

MondayMar 29, 2021 11:54 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Orders First Functional Mushroom Shipment for Global E-Commerce Portal

PULL expands into EU through initial sale of cannabis oil extracts to German pharmaceutical company Sale to Germany expected to pave way for additional supply agreements throughout Europe Company orders first shipment of functional mushroom products for direct-to-consumer e-commerce portal, expects $15,000 gross monthly sales for each formulation PULL’s new state-of-the-art facility constructed to EU GMP standards for worldwide exports With a focus on the cannabis, hemp, functional mushrooms and rapidly emerging psychedelic sectors, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a Canadian plant-based extraction company, is steadily increasing its market share through the achievement of several important…

FridayMar 26, 2021 12:13 pm

Educational App That Demonstrates Psychedelics Effects on the Brain Launches

Psychedelic drugs such as psilocybin mushrooms have been used for centuries in various cultures across the globe before becoming popular in the Western world in the 1960s. Recently, the substances, most of which are naturally occurring substances, have been utilized in research studies in various parts of the world, with the objective being to help develop treatments for various mental health conditions. For instance, a study conducted by researchers from Johns Hopkins Medicine found that two doses of psilocybin produced large and fast reduction in the depressive symptoms of study participants, with some achieving remission through a one month follow-up.…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000